FOLFIRINOX Induction Chemotherapy for Synchronous Liver Metastases

SYNCHRONOX is a multicenter cohort (retrospective then prospective) intending to include 550 patients with mid or low rectal adenocarcinoma (pMMR, T3-T4 and/or N+) and resectable synchronous liver metastases, treated upfront with at least two cycles of induction FOLFIRINOX chemotherapy. The primary objective is to determine, at 18 months, the R0 resection rate of both tumor sites (rectum and liver), while secondary objectives focus on 3 year overall and progression free survival, radiological and pathological responses, postoperative morbidity and mortality, and comparison of the different surgical strategies after FOLFIRINOX.

NCT Number	NCT07467434
Lead Sponsor	Assistance Publique - Hôpitaux de Paris
Conditions	Rectal Cancer, Synchronous Liver Metastases, Antineoplastic Combined Chemotherapy Protocols, Surgical Therapy
Enrollment	550 participants
Start Date	2026-05-01
Primary Completion	2030-11-01 (estimated)
Study Completion	2034-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-09